1.646.889.1200|info@lifescipublicrelations.com

Abpro, NJCTTQ To Develop Bispecific Antibodies in Immuno-oncology

//Abpro, NJCTTQ To Develop Bispecific Antibodies in Immuno-oncology

Abpro, NJCTTQ To Develop Bispecific Antibodies in Immuno-oncology

Antibody company Abpro Corp. (Woburn, Mass.) has partnered with Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (NJCTTQ) to use Abpro’s DiversImmune antibody discovery platform to develop multiple bispecific antibodies, including T cell engagers, to treat cancer.

By | 2019-03-01T13:16:32-04:00 February 28th, 2019|News|Comments Off on Abpro, NJCTTQ To Develop Bispecific Antibodies in Immuno-oncology

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.